Background: The term vitamin E describes a family of 8 vitamers, 1 of which is a-tocopherol, that is essential for human health.
Introduction
Vitamin E is a collective term that refers to 2 groups of fatsoluble compounds that comprise 4 tocopherols (a, b, d, g) and 4 tocotrienols (a, b, d, g), of which 2 are of the greatest public health importance: a-tocopherol, which is biologically most active in vivo and essential for human health, and g-tocopherol, which is usually regarded to be most abundant in foods but less well utilized in humans (1) . In developing countries, where micronutrient deficiencies are endemic, vitamin E deficiency may be a public health problem, but it remains virtually unassessed. Although molecular mechanisms, functions, and clinical effects of varying vitamin E intakes through diet and supplementation represent active areas of research in high-income, often betternourished societies, a review published in 2011 surprisingly found only 19 population-based assessments of vitamin E status published from low-to middle-income countries between 1992 and 2009 (11, 3 , and 5 among children, the elderly, and groups of mixed ages, respectively). Based on a plasma a-tocopherol concentration cutoff that varied from 12 to 14 mmol/L, the prevalence of vitamin E deficiency ranged from 6% to 70%, 27% to 55%, and 4% to 70% in each of these population groups (2) . Other recent population studies of women and school-aged children in Bangladesh and Nepal have revealed prevalences of ;50% and higher for a-tocopherol concentrations <12 mmol/L (3, 4) . A recent study in Bangladesh reported early-gestation vitamin E deficiency (plasma a-tocopherol <12 mmol/L) to be associated with a nearly 2-fold increased risk of miscarriage (5) . This compilation of evidence suggests that vitamin E deficiency could be a major public health problem while revealing at the same time a gaping hole in knowledge about its extent, severity, and epidemiology for all ages in undernourished and nutrition-transitioning societies. Sparser yet are population data on g-tocopherol status in low-to middleincome countries, for which health effects and an interpretation of circulating concentrations remain undefined.
A barrier to acquiring population data on vitamin E status relates to the difficulty and expense of measuring plasma or serum tocopherols by HPLC, which is the method of choice for assessing tocopherol concentrations but requires technical skills and resources often lacking in low-resource settings. As a result, biospecimens must be collected and typically transported in dry ice or liquid nitrogen to regional or global reference laboratories for vitamin E measurements, adding further costs and time for assessment (5) . Suitable alternatives are needed for more rapid, less expensive, on-site assessments to accelerate the accrual of data for better assessing and understanding the extent to which vitamin E deficiency affects public health. A similar need exists for most other micronutrients (6) . Identifying plasma proteins that are reliably associated with plasma concentrations of a-tocopherol and other micronutrients could pave the way for less expensive and more rapid field-based protein assays (e.g., with highly specific antibody panels that target sets of plasma proteins) to estimate multiple nutrient status distributions and to better target prevention efforts in the future.
We recently demonstrated that plasma proteomics offers a useful approach for identifying protein biomarkers for conventional micronutrient status indicators (7) . The validity of plasma proteomics for assessing micronutrient status rests on 2 axioms: 1) that nutrients are absorbed, transported, metabolized, and interact-directly or through systemic metabolic circuitsthrough a vast set of proteins, and 2) that detectable plasma nutrient:protein associations reliably reflect systemic covariation under a wide range of health and disease states. Combining mass spectrometry, bioinformatics, and statistical modeling (8) , we reported correlations between the plasma concentrations of 5 micronutrients (vitamins A, D, and E and copper and selenium) and relative abundance of 5 transport proteins for these nutrients in Nepali children. In this proof-of-concept analysis, a-tocopherol was most strongly correlated with apoC-III (r = 0.64), a principal constituent of VLDLs (9) to which the vitamer is bound when secreted from the liver into circulation (10) . This finding was consistent with a study of young Canadian adults, among whom apoC-III was 1 of 7 proteins most strongly associated with plasma a-tocopherol (11) . We further derived a preliminary 2-protein model [apoC-III and regulator of G-protein signaling 8 (RGS8) 8 ] that explained 65% of the variance in plasma a-tocopherol (7), suggesting that plasma proteins can potentially predict vitamin E status. This analysis extends preliminary findings to specify a large, chance-adjusted plasma a-tocopherome (proteins covarying with vitamin E status), offers a more complete model for predicting plasma a-tocopherol, and reports a smaller, less predictive plasma g-tocopherome.
Methods
Field trial and cohort follow-up study. Subjects whose biospecimens were analyzed for this study were members of a cohort of 6-to 8-y-old children living in Sarlahi District, Nepal, whose mothers participated in a 5-arm antenatal micronutrient supplementation trial between 1999 and 2001 (12) and whose health and nutritional status were reexamined between 2006 and 2008. In that trial, women received 1 of 5 different supplements in recommended dietary allowance amounts (folic acid, iron-folic acid, iron-folic acid and zinc, a multiple micronutrient supplement, or placebo) from early pregnancy through 3 mo postpartum (12) ; in addition, a small proportion of the children (;8%) received either iron-folic acid or zinc supplements from 12 to 36 mo of age (4) . During the follow-up, we assessed socioeconomic status, childrenÕs 7-d food frequencies and morbidity, and anthropometry by reported methods (13, 14) . Venous blood was drawn, processed into plasma aliquots, shipped under vapor-phase liquid nitrogen, and stored at 280°C in the micronutrient analysis laboratory at Johns Hopkins University in Baltimore, Maryland (4). Informed consents were obtained during the original trial and follow-up study. All protocols were approved by institutional review boards in Kathmandu, Nepal, and at Johns Hopkins University. The original trial was registered with clinicaltrials.gov: NCT0011527. Reports on child health (13) , growth (14) , cognition (15) , and micronutrient status (4) have appeared previously.
Micronutrient and proteomics study. In the original trial, 4998 mothers gave birth to 4130 infants, 3524 of whom were contacted at ages 6-8 y for follow-up. Venous blood was drawn from 3305 children; sufficient plasma existed for 2726. Complete trial-to-follow-up data and bioarchives were available for 2130 children, 200 of whom were randomly sampled from each original maternal supplement group to yield 1000 child plasma samples for micronutrient analyses, including a-and g-tocopherol (4). From these 1000 samples, we randomly sampled 50% (n = 100 per original trial group) to obtain 500 specimens for protein analysis.
Plasma a-and g-tocopherol analyses. Plasma a-tocopherol and g-tocopherol were analyzed following the procedure of Yamini et al. (16) on a reverse-phase Waters Alliance 2795 HPLC system (Waters Corporation) with a quaternary gradient pump, autosampler, Waters 2996 photodiode array detector, and Empower 2 software (3, 4). Separation was achieved using a Supelcosil LC-18 column in combination with a LC-18 2-cm 3 4.0-mm guard column (Sigma-Aldrich). Tocopherols were assessed at 295 nm. The National Institute of Standards and Technology standard reference material SRM968d was used for calibration, with 3.7% and 8.6% coefficients of variation for aand g-tocopherol, respectively, across repeated runs of the reference material. Total cholesterol and TGs had previously been measured (Cholestech) (13) .
Plasma proteomics analysis. Procedures developed for this study have been described (6) . Briefly, 500 plasma samples were 85-90% immunedepleted of 6 high-abundance proteins (albumin, immunoglobulins G and A, transferrin, haptoglobin, and antitrypsin) using the Multiple Affinity Removal LC Column Human 6 system (Agilent Technologies). Protein extracts (100 mg each) were precipitated with tricarboxylic acid/ acetone, digested with trypsin, labeled with an iTRAQ reagent (SigmaAldrich), fractionated by strong cation exchange chromatography, and analyzed on an LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific) in experiments that consisted of 7 samples plus 1 pooled sample for quality control and the random assignment of a unique iTRAQ reagent to each sample. The pooled sample was later found to be unnecessary for quantifying or normalizing data from multiple iTRAQ experiments (8) . Tandem mass spectra were extracted and searched against the RefSeq 40 database using Mascot (Matrix Science) through Proteome Discoverer software version 1.3 (Thermo Fisher Scientific) to quantify proteins with respect to the within-iTRAQ medians of log 2 -transformed and normalized reporter ion intensities derived from Proteome Discoverer (7, 8) . Data were obtained from 72 iTRAQ experiments with an average of 589 proteins (SD = 65) quantified per experiment. In all, 4705 proteins were detected, with 982 quantified in >10% (n > 50) of all samples (7) and 146 proteins measured in all samples, representing the analyzed plasma proteome for this study.
Statistical analysis. General characteristics of study children were expressed as mean 6 SD or median (IQR) for continuous variables and percentage per category for discrete variables. Plasma a-and g-tocopherol distributions that were skewed to the right were corrected with natural log 2 transformations. For a-tocopherol, the log 2 -transformed (7) and untransformed distributions revealed virtually the same results; thus, for simplicity, only untransformed a-tocopherol analyses are presented. Because the skew was more pronounced for plasma g-tocopherol, results from the log 2 -transformed g-tocopherol analysis are presented. Linear mixed-effects (LME) models were fitted via restricted maximum likelihood estimation procedures that combined complete proteomics data across all 72 iTRAQ experiments as previously described (7, 8) . This model produced the following expected values of a-and log 2 g-tocopherol concentrations for each individual protein:
where N rk denotes the observed (for a-tocopherol) or log 2 -transformed (for g-tocopherol) plasma nutrient concentration, k is the index for each sample in each r iTRAQ experiment, and P rk is the relative abundance for each protein for each vitamer analysis. The parameter estimate b 0 is the intercept that is the overall mean concentration of each tocopherol; B r denotes the random deviation from this mean in experiment r; and b 1 estimates the slope of the nutrient:protein association, denoting absolute (in mmol/L) and relative (%) changes in a-and g-tocopherol, respectively, per 100% increase in relative abundance of each protein. Statistical significance of a protein-nutrient association was assessed via a 2-sided hypothesis test for b 1 = 0.
To account for multiple comparisons, a q value, which is a chanceadjusted P value that represents a false discovery rate (17) , is reported for each single protein-nutrient association. All proteins classified into a plasma a-or g-tocopherol proteome (n = 119 and 12, respectively) were required to meet a false discovery rate threshold of q < 0.10. Summary tables were generated separately for positively and negatively associated proteins for a-tocopherol and combined for g-tocopherol, providing for each protein its respective Human Genome Organization gene symbol (18) , number of measured protein values, protein:nutrient correlation (r), variance in nutrient concentration explained by the protein (R 2 ), q, the slope (b 1 ) with an associated P value for the test of b 1 = 0, and GenInfo identifier accession number (19) .
Before fitting a multiple protein regression model for predicting vitamin E status, missing protein values in the database were imputed (20) employing a regression-based approach that assumed that the nutrient-protein relation observed in the complete data set could be used to infer missing protein values. Thus, for each vitamer and protein in their proteome (i.e., n = 119 and 12 for a-and g-tocopherol, respectively), protein relative abundance values were regressed on nutrient concentration and predicted values from this regression were used to impute missing values. This imputation was conducted 10 times for each nutrient based on the assumption that this number of imputations would suffice to account for the variability among imputed values (differences in individual estimates derived from the analysis of each imputed dataset). The LME model was fitted to each of the imputed data sets, and the averages of the 10 model estimates, adjusted for between-and within-imputation variance, were adopted as the final model estimates.
The ability of plasma proteins to predict vitamin E status was explored using the combined dataset of measured and imputed protein values. This involved fitting a single multiple-protein model, built for each of the 2 vitamers E, by a forward stepwise inclusion procedure based on the variable inclusion P value criterion that started with the protein exhibiting the lowest q value in the single-protein LME models and allowing the model to select additional covariates from a set of proteins singly associated with each vitamer with a q < 0.10 and P < 0.0001. The Akaike information criterion (AIC), which is a function of the model likelihood, the number of parameters in the model (21, 22) , and the likelihood test P value for b 1 = 0, were used to assess model fit and complexity. Lower values of the AIC indicate a relative improvement in model fit and better external validity (21) . Stepwise inclusion of the protein with the smallest P value continued until no protein from each vitamer-specific set could reduce the AIC by $30. In an effort to discover additional potential predictors, a second tier of protein candidates was identified for future consideration and population testing by repeating a series of forward stepwise procedures for proteins meeting either q < 0.1 or q < 0.01 criteria that excluded protein covariates fitted to each preceding model until no additional proteins met the above AIC criterion. Data analyses were carried out using in-house-developed open-source software implemented in the statistical environment R (23). 
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1 Sixty-two proteins quantified by mass spectrometry and estimated by LME modeling in .10% of the samples that were positively correlated with plasma a-tocopherol (P , 0.01, q , 0.10), listed in increasing order of q, defined as positively associated protein biomarkers of a plasma a-tocopherome. HUGO, Human Genome Organization; LME, linear mixed effects. 2 Number (n) of child plasma samples in which a protein was detected and quantified by iTRAQ tandem mass spectrometry (excludes subsequent imputations required for multivariable LME models). 3 Univariate LME-modeled positive slope indicating change in plasma a-tocopherol concentration (in mmol/L) per 100% increase in relative abundance of each listed plasma protein. 
TABLE 2
Plasma proteins negatively associated with plasma a-tocopherol in children of rural Nepal aged 6-8 y (n = 500)
Results
Study children were moderately underweight, stunted, and thin, with 48%, 39%, and 16% below 22 z scores of the WHO international anthropometric weight-for-age, height-for-age, and body mass index-for-age references, respectively (24) . Children in this sample were comparable in nutritional status to the larger sample of children who underwent micronutrient analysis (4) (Supplemental Table 1 ). Except for dairy (i.e., local yogurt), few children regularly consumed ($3 times in past week) foods of animal origin, reflecting the usual diet in this region (25) . Few children (3-8%) reported symptoms of illness in the previous 7 d. Plasma a-tocopherol concentrations (mean 6 SD) were 12. Based on single-protein LME models, 119 proteins were associated with plasma a-tocopherol (all q < 0.10). Sixty-one proteins were positively correlated with a-tocopherol ( Table 1) , most notably aposA-C, E, and L. Positive correlates also included multifunctional proteins involved in vascular lipid, vitamin, mineral, and hormonal transport [retinol-binding protein 4, APOsD and M (27) , transthyretin (28), insulin-like growth factor-binding protein 3, insulin-like growth factor acid-labile subunit, and selenoprotein P isoform 1 (29) ].
Others included proteins that are active in innate immunity [cathelicidin antimicrobial peptide (30) (Table 1) .
Fifty-eight plasma proteins were negatively correlated with a-tocopherol ( (45), intercellular and vascular cell adhesion molecules 2 and 1, respectively (46) , and desmoglein (47)]. The a-tocopherol level was also negatively correlated with proteins involved in anticoagulative control [serine peptidase inhibitor, clade G, member 1 (SERPING1), also known as C1-inh (48) A correlation (r) matrix of 44 proteins in the plasma a-tocopherome, restricted to q < 0.01 and where r is re-expressed as r 3 10 2 to enable visualization ( Figure 1 ) revealed highly variable protein-protein correlations with estimates ranging from 0.16 to 0.93 and 20.13 to 20.85, reflecting a diverse proteome that can potentially predict vitamin E status.
Using the forward stepwise approach of building a multivariable LME model starting with the most predictive protein, we built a model with the following 6 proteins, each of which met the criteria of having the smallest P value, a q value <0.1, and through its inclusion reducing the model AIC by at least 30 units: aposC-II and B, PKM, forkhead box 04, unc5 homolog C, and RGS8, accounting for 71% of variability in plasma a-tocopherol ( Table 3) .
Within this population sample, the 6-protein model predicted prevalences of vitamin E deficiency (a-tocopherol <12 mmol/L) (1, 26) and moderate or worse deficiency (<9.3 mmol/L) (3, 4) of 51.4% (95% CI: 46.4, 56.3) and 12.7% (CI: 8.9, 16.4) compared with measured prevalences of 54.8% and 17.6%, respectively. Additional analyses identified a second tier of 9 proteins that, although not in the model because of collinearity with the first 6, explained additional variability in a-tocopherol (see Table 3 footnote).
Twelve plasma proteins were associated with the log 2 -transformed g-tocopherol distribution (q < 0.10) ( Table 4) . Modeling these proteins after imputation identified 2 covariates (apoC-III and Misato homolog 1), explaining only 20% of the variability in g-tocopherol and thus insufficient for prediction. 1 Fifty-nine proteins quantified by mass spectrometry and estimated by LME modeling in .10% of the samples that were negatively correlated with plasma a-tocopherol (P , 0.01, q , 0.10), listed in increasing order of q, defined as negatively associated protein biomarkers of a plasma a-tocopherome. HUGO, Human Genome Organization; IgG, immunoglobulin G; LME, linear mixed effects; MIF4G, middle domain of eukaryotic initiation factor 4G. 2 Number (n) of child plasma samples in which a protein was detected and quantified by iTRAQ mass spectrometry (excludes subsequent imputations required for multivariable LME models). 3 Univariate LME-modeled negative slope indicating change in plasma a-tocopherol concentration (in mmol/L) per 100% increase in relative abundance of each listed plasma protein.
Discussion
Vitamin E deficiency likely exists with health consequence (1-5) but remains latent and is thus largely ignored in most undernourished societies. Encouraged by an earlier finding of strong association between plasma a-tocopherol and apoC-III (7), this analysis sought to detect through quantitative proteomics a cluster of biomarkers that could be modeled to predict a-tocopherol concentrations in a generally undernourished population. The public health utility of this discovery approach lies in its potential to guide the development of targeted, multiprotein quantification assays that may be able to simultaneously estimate the prevalence of multiple micronutrient deficiencies, including vitamin E, on a less costly, faster platform (e.g., using FIGURE 1 Matrix of correlation coefficients for pairs of LME-based estimates of relative abundance and plasma a-tocopherol concentration for proteins associated with a-tocopherol, restricted to associations with q , 0.01 (n = 44), in children of rural Nepal aged 6-8 y (n = 500). Blue depicts proteins that share a positive correlation, red shows a negative correlation, and darker colors represent a stronger association. All correlation coefficients (r) are presented as r 3 10 2 to improve visualization. Blank cells represent unobserved protein pairs in any of the same participants. ALDH9A1, aldehyde dehydrogenase 9A1; B2M, b-2-microglobulin; C4orf22, chromosome 4 open reading frame 22; C9, complement component 9; CD44, CD44 antigen isoform 4; CDH, cadherin 1, type 1; CNDP1, carnosine dipeptidase; EVI5, ecotropic viral integration site 5; FOXO4, forkhead box protein O4; GGH, g-glutamyl hydrolase; ICAM2, intercellular adhesion molecule 2; IFRD2, interferon-related developmental regulator 2; IGFALS, insulin-like growth factor-binding protein, acid-labile subunit isoform 2; IGFBP3, insulin-like growth factor-binding protein 3 isoform b; KIF20B, kinesin-like protein KIF20B; KLF17, Kruppel-like factor 17; LME, linear mixed effects; LRG1, leucine-rich a-2-glycoprotein 1; LRRC47, leucine-rich repeat containing 47; MSTO1, Misato homolog 1; NSUN6, NOP2/Sun domain family, member 6; ORM1, orosomucoid 1; PKM, pyruvate kinase, muscle; PON1, paraoxonase 1; PRG2, proteoglycan 2; PRG4, proteoglycan 4 isoform D; PROC; protein C; QSOX1, quiescin Q6 sulfhydryl oxidase 1; RBP4, retinol-binding protein 4; SERPINA7, serpin peptidase inhibitor, clade A, member 7; TMF1, TATA element modulatory factor; TNIP1, TNFAIP-interacting protein 1; TTR, transthyretin; UNC5C, Unc5 homolog C.
antibody methods). To our knowledge, such a multinutrient proteomics system does not yet exist, but a first step toward achieving this potential is to discover, quantify, and evaluate protein candidates for such a system. This study revealed a plasma a-tocopherome that consisted of 119 of 982 proteins in a population of Nepali children in whom vitamin E and other nutritional deficiencies, as well as inflammation, were common (4). Restricting admissible proteins to a false discovery rate <10% offered reasonable assurance against spurious associations of proteins with a-tocopherol, although 44 proteins also met a more stringent threshold of 1%. After imputing missing values for multivariable regression analysis and employing a stepwise method that limited the selection of proteins based on the strength of their contribution to predicting a-tocopherol, 6 proteins entered a model that explained 71% of the variation in plasma a-tocopherol and predicted an in-sample prevalence of vitamin E deficiency of 51%, which was similar to a prevalence of 54% based on a-tocopherol concentrations at a conventional cutoff of <12 mmol/L (1, 26) . Although promising, the unavailability of an independent population to retest the model merits caution in interpreting these results. Intriguingly, the 2 negative correlates in the model, PKM and RGS8, could be functional markers of depleted vitamin E nutriture. PKM, an intermediate of glycolysis, is known to be released from erythrocytes and other cells damaged by vitamin E deficiency (54) , and RGS8, a cytosolic G-protein signaling regulator, concentrates in the Purkinje cells of the cerebellum (55) , where neurological lesions of vitamin E deficiency seem to be most pronounced (56) .
Although relative abundance estimation permits nutrient: protein pairs to be evaluated for direction, strength, and predictivity of association, absolute quantification of candidate proteins will be needed to test the ability of a protein-based model for predicting status and the prevalence of vitamin E deficiency. In addition, because the optimal model could vary across populations, including those populations that are better nourished, 9 additional proteins were identified that may be exchangeable or add power for predicting plasma a-tocopherol, thus increasing the number of candidate proteins to target for future absolute quantification.
Beyond prediction, a novel advantage of a plasma proteomics approach is the opportunity it affords for discovering plausible, functional suites of biomarkers associated with nutrient status. Criteria of plausibility of association include prior evidence of 1) direct nutrient:protein molecular interaction (e.g., in transport or biogenesis); 2) colocalization in which molecular linkages are likely, if not established [e.g., phospholipid-rich membranes for a-tocopherol (57)], or 3) covariation between the nutrient and metabolic systems in which associated proteins participate [e.g., immune (58) , coagulative (59), or nervous (60-62) systems]. The first criterion is illustrated by a-tocopherolÕs lipid antioxidant (63, 64) and nonantioxidant roles in regulating gene expression, lipid metabolism (60) (61) (62) , and membrane homeostasis and repair (64) . Strong positive correlations of a-tocopherol with aposA (I, II), B, C (I-IV), E, and L likely reflect the vitamerÕs postabsorptional and hepatic release into circulation, where it admixes with virtually all lipoproteins (9, 10, 65) . Positive correlation with some lipocalins (retinol-binding protein 4 and apos D and M) may similarly reflect the carriage of a-tocopherol with low-molecular-weight lipids transported by these proteins (27) . However, correlations with lipid transporters may also represent comodulatory roles with a-tocopherol in cross-talking immune (66, 67) , inflammatory (67) (68) (69) , coagulative (70) , and neurological (60, 61, 66) systems. In addition, the observed positive correlation between plasma a-tocopherol and the protein afamin, a multifunctional albumin-family glycoprotein, may reflect more remote interactions because although afamin transports a-tocopherol in extravascular fluids it does not do so in plasma (71) .
In systematic terms, a-tocopherol attenuates inflammation by suppressing, for example, the expression of TNF-a, IL1b and -6, platelet aggregation, monocyte adhesion, and oxidative stress (58, 68, 72) . These homeostatic influences may give rise to the vitamerÕs negative correlations with positive acute-phase reactants such as orosomucoid 1 and 2, ceruloplasmin (37) , and lipocalin-2 (66), as well as effectors in complement activation (40) , wound repair (39, 64) Stepwise LME model explaining variability in plasma a-tocopherol by candidate proteins in a plasma a-tocopherome children of rural Nepal aged 6-8 y (n = 500) protein, which activates macrophages (38) ]. Broad effects of a-tocopherol in the anticoagulant pathway may be expected to give rise to positive correlations with cytoprotective proteins C (31) and Z (32), which are thought to dampen coagulation cascades and prevent thrombosis. Associations between a-tocopherol and some biomarkers of inflammation and coagulation may at first seem contradictory, such as a negative correlation with SERPING1. This serine protease inhibitor exerts anti-inflammatory activity by inhibiting activation of the classic complement pathway and suppressing premature activation of downstream factors in the coagulation cascade (48) . However, these actions require a rise in SERPING1 abundance during the initial response to inflammation (48) , potentially explaining the observed negative association with plasma a-tocopherol. Alternatively, positive correlations with enzymes that upregulate coagulation such as factors II (thrombin), VII, XI, XIII A1, and XIII B could reflect a-tocopherolÕs association with inactive zymogen precursors of these proteins that circulate in high abundance under noninflamed, homeostatic conditions. Associations of these types would be consistent with roles a-tocopherol may play in promoting readiness of the complement, coagulation and kinin-bradykinin systems to respond to challenges and, once activated, aiding to minimize tissue injury.
Many plasma a-tocopherome proteins localize to phospholipidrich membranes of neural tissues, where a-tocopherol is abundant, neuroprotective, and maintains redox homeostasis (56, 60) . Neural tissue is also where early lesions of vitamin E deficiency may occur (74) , leading to the loss of neuromuscular function (60, 61) . In a rare controlled therapeutic study, malnourished, vitamin E-deficient Indian children showed marked neurological improvement after 6 wk of vitamin E supplementation (75) . In our study, plasma a-tocopherome biomarkers included proteins known to be involved in neuraxonal guidance [unc5 homolog C (34)]; neuromodulation [prostaglandin D2 synthase (76), apoA-1 (62), kininogen-1 (77), and lipocalin-2 (66)]; cilium and axonemal conformation, motility, attachment, and motor function [dynein, axonemal assembly factor 1 (78), kinesin-like protein (33), BardetBiedl syndrome 7, and tubulin tyrosine ligase-like family, member 8 (78)]; cargo transfer, vesiculation, and cytosolic transport [clathrin (79) , dynein (78) , and kinesin isoforms (33) ]; and redox homeostasis [peroxiredoxin-2 (52), thioredoxin (53), queiscin-sulfhydryl oxidase (51), paraoxonases (36) , and selenoprotein P1 (29) ], all functions required for neuromuscular health.
A far smaller, less significant, and nonpredictive plasma proteome was associated with plasma g-tocopherol and comprised 12 proteins at a false discovery rate <10%, 8 of which also correlated with a-tocopherol. The striking differences between a-and g-tocopheromes may reflect the extent to which the a-tocopherol transfer protein, synthesized in the liver and brain, actively facilitates the circulation of a-tocopherol to tissues to promote the functions ascribed to vitamin E (65) .
In summary, an unbiased, quantitative proteomics approach identified 6 plasma proteins whose relative abundance explained sufficient variability in plasma a-tocopherol to predict with reasonable accuracy the in-sample prevalence of vitamin E deficiency. The study detected 119 protein correlates of vitamin E (a plasma a-tocopherome) of diverse function that can potentially serve as biomarkers of the physiological and disease processes associated with vitamin E deficiency. Next steps involve absolute quantification of targeted proteins, verification of their ability to predict vitamin E deficiency, migration of their measurement onto a simpler protein assay platform, and further testing in populations. 1 Twelve proteins quantified by mass spectrometry and estimated by linear mixed-effects modeling in .10% of the samples (50 , n # 500) that are correlated with plasma log 2 g-tocopherol, subjected to a false discovery rate cutoff of 10% (q , 0.10), and listed in increasing order of q are defined as candidate protein biomarkers for a plasma g-tocopherome. 2 Percentage change in plasma g-tocopherol (in mmol/L) per 100% increase in relative protein abundance. 3 GenInfo Identifier sequence number as assigned to all nucleotide and protein sequences by the National Center for Biotechnology
Information at the National Library of Medicine, NIH (18) . 4 Proteins included in a stepwise regression model that explained 20% of the variability in plasma g-tocopherol concentration.
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